NAS:MOR (Germany)
Â
Business Description
Description
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.19 | |||||
| Equity-to-Asset | -0.01 | |||||
| Debt-to-Equity | -12.09 | |||||
| Debt-to-EBITDA | -0.66 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -0.7 | |||||
| Beneish M-Score | -1.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 30.1 | |||||
| 3-Year EBITDA Growth Rate | -105.2 | |||||
| 3-Year EPS without NRI Growth Rate | -104.9 | |||||
| 3-Year FCF Growth Rate | -138.2 | |||||
| 3-Year Book Growth Rate | -22.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.51 | |||||
| 9-Day RSI | 71.38 | |||||
| 14-Day RSI | 67.28 | |||||
| 6-1 Month Momentum % | -35.5 | |||||
| 12-1 Month Momentum % | -55.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.98 | |||||
| Quick Ratio | 2.91 | |||||
| Cash Ratio | 2.29 | |||||
| Days Inventory | 158.64 | |||||
| Days Sales Outstanding | 130.1 | |||||
| Days Payable | 630.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.92 | |||||
| Operating Margin % | -98.82 | |||||
| Net Margin % | -345.26 | |||||
| ROE % | -276.51 | |||||
| ROA % | -35.95 | |||||
| ROIC % | -17.23 | |||||
| ROC (Joel Greenblatt) % | -1023.83 | |||||
| ROCE % | -23.94 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.51 | |||||
| EV-to-EBIT | -0.43 | |||||
| EV-to-EBITDA | -0.44 | |||||
| EV-to-Revenue | 0.96 | |||||
| EV-to-FCF | -0.36 | |||||
| Price-to-Median-PS-Value | 0.12 | |||||
| Earnings Yield (Greenblatt) % | -232.56 |
